Oracle Health Sciences announced the availability of the latest version of Oracle Health Sciences Translational Research Center, a platform that enables secondary use of electronic health records, administrative data and omics data to help accelerate biomarker identification for drug discovery, clinical development and translational research.
The new release expands Oracle Health Sciences Translational Research Center’s patient-centric query capabilities, enabling users to create searches that span phenotype and genotype attributes to quickly identify targeted patient populations. For example, users can now set search parameters for a patient’s demographics, cost and treatment timeline, combined with a variety of specific genetic variants in a single search to unlock new insights and advance personalized medicine initiatives. Users can also create gene-centric searches, which enable researchers to retrieve and further analyze all available omics data for particular gene sets of interest within a large data set.
This new release integrates genomic visualization tools that provide holistic views of multiple omics data modalities to enable systems biology-based approaches essential for understanding disease.
In addition to Oracle Health Sciences Translational Research Center’s existing adapters for loading customer-generated molecular profiling data – as well as public domain data from sources such as Ensembl, The Cancer Genome Atlas, 1000 Genomes and Pathway Commons – the new release extends the omics databank by providing pre-built adapters for RNA sequencing (RNA-seq) and SIFT/Polyphen data sets, further speeding time-to-value for end users. Running on Oracle Exadata Database Machine, Oracle Health Sciences Translational Research Center provides the high performance and extreme scalability required to deliver real-time query response against extremely large whole genome data sets. Oracle Health Sciences Translational Research Center can be deployed on-premise, in the HIPAA-certified Oracle Health Sciences Cloud, or in a hybrid model that leverages both to provide organizations with maximum flexibility in their deployment options.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.